Drug Profile
Linaclotide - Ironwood Pharmaceuticals
Alternative Names: ASP-0456; ASP-456; Constella; Linaclotide acetate; Linzess; MD-1100; MD-7246; MM-416775Latest Information Update: 10 Jan 2024
Price :
$50
*
At a glance
- Originator Microbia
- Developer AbbVie; Astellas Pharma; AstraZeneca; Ironwood Pharmaceuticals
- Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Non-opioid analgesics; Oligopeptides
- Mechanism of Action Enterotoxin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Constipation; Irritable bowel syndrome
- No development reported Visceral pain